NEURONTIN Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Neurontin, and when can generic versions of Neurontin launch?
Neurontin is a drug marketed by Viatris and is included in three NDAs.
The generic ingredient in NEURONTIN is gabapentin. There are twenty-nine drug master file entries for this compound. Seventy-eight suppliers are listed for this compound. Additional details are available on the gabapentin profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Neurontin
A generic version of NEURONTIN was approved as gabapentin by ACTAVIS ELIZABETH on September 12th, 2003.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for NEURONTIN?
- What are the global sales for NEURONTIN?
- What is Average Wholesale Price for NEURONTIN?
Summary for NEURONTIN
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 3 |
| Finished Product Suppliers / Packagers: | 2 |
| Raw Ingredient (Bulk) Api Vendors: | 151 |
| Clinical Trials: | 126 |
| Patent Applications: | 4,475 |
| Drug Prices: | Drug price information for NEURONTIN |
| Drug Sales Revenues: | Drug sales revenues for NEURONTIN |
| What excipients (inactive ingredients) are in NEURONTIN? | NEURONTIN excipients list |
| DailyMed Link: | NEURONTIN at DailyMed |
Recent Clinical Trials for NEURONTIN
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Dianne Lou | Phase 1/Phase 2 |
| Viatris Specialty LLC | Phase 4 |
| CAMC Health System | Phase 4 |
Pharmacology for NEURONTIN
| Physiological Effect | Decreased Central Nervous System Disorganized Electrical Activity |
US Patents and Regulatory Information for NEURONTIN
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Viatris | NEURONTIN | gabapentin | CAPSULE;ORAL | 020235-001 | Dec 30, 1993 | AB | RX | Yes | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
| Viatris | NEURONTIN | gabapentin | SOLUTION;ORAL | 021129-001 | Mar 2, 2000 | AA | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
| Viatris | NEURONTIN | gabapentin | CAPSULE;ORAL | 020235-002 | Dec 30, 1993 | AB | RX | Yes | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
| Viatris | NEURONTIN | gabapentin | CAPSULE;ORAL | 020235-003 | Dec 30, 1993 | AB | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for NEURONTIN
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Viatris | NEURONTIN | gabapentin | SOLUTION;ORAL | 021129-001 | Mar 2, 2000 | ⤷ Sign Up | ⤷ Sign Up |
| Viatris | NEURONTIN | gabapentin | CAPSULE;ORAL | 020235-003 | Dec 30, 1993 | ⤷ Sign Up | ⤷ Sign Up |
| Viatris | NEURONTIN | gabapentin | CAPSULE;ORAL | 020235-003 | Dec 30, 1993 | ⤷ Sign Up | ⤷ Sign Up |
| Viatris | NEURONTIN | gabapentin | CAPSULE;ORAL | 020235-001 | Dec 30, 1993 | ⤷ Sign Up | ⤷ Sign Up |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for NEURONTIN
See the table below for patents covering NEURONTIN around the world.
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2024 - 2025
NCE-1 Patent Challenge Dates 2024 - 2025
Trigger-based marketing for the life sciences
Get DrugPatentWatch Business Intelligence Reports at Amazon.com
DrugChatter - AI-based answers to questions about drugs
RxJam - Digital Marketing for Life Sciences
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2024, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch
Follow DrugPatentWatch:
